Handelsavisen
prelaunch
Companies Healthcare SURK.NS
SU
SURK.NS NSE (India) Healthcare Facilities & Services

Suraksha Diagnostic Ltd

$304,05
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
18,3 %
ROE
15,1 %
Net margin
12,6 %
Debt / equity
0,42
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Business description not yet wired for this issuer.

Business. Suraksha Diagnostic Ltd (SURK.NS) is a healthcare services company operating within the Healthcare Facilities & Services industry. The firm generates service revenue through its diagnostic operations, though specific segment or geographic breakdowns are not disclosed. Headquartered in India, the company is primarily listed on the National Stock Exchange of India.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
HOLD1 analysts
0 buy1 hold0 sell
Avg 12m price target285,00

Analyst recommendations

1 analysts · consensus Hold
Buy0
Hold1
Sell0
12-month price target
285,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
1 analysts · indicative
Ownership
not yet wired
Profitability
15,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SURK.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SURK.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Suraksha Diagnostic Ltd (SURK.NS) is a healthcare services company operating within the Healthcare Facilities & Services industry. The firm generates service revenue through its diagnostic operations, though specific segment or geographic breakdowns are not disclosed. Headquartered in India, the company is primarily listed on the National Stock Exchange of India.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    Suraksha Diagnostic Ltd provides diagnostic services and operates in the healthcare facilities and services industry, generating revenue primarily through laboratory testing and related healthcare services.

    Suraksha Diagnostic Ltd is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector, with a high confidence level of 0.92 according to verified market data.

    Suraksha Diagnostic Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.42, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.1, suggesting it has sufficient short-term assets to cover its short-term liabilities, though not with a significant buffer. Free cash flow stands at INR 242.5 million, which is a positive indicator of the company's ability to generate cash after capital expenditures.

    In terms of profitability, the company's return on equity (ROE) is 15.07%, and its return on assets (ROA) is 9.54%. These figures are strong and suggest that the company is effectively utilizing its equity and assets to generate profits. The operating margin, calculated as operating income divided by revenue, is 18.33%, which is a key metric for assessing operational efficiency in the healthcare services industry.

    The company's revenue is primarily concentrated in its core diagnostic services, with no significant diversification into other segments. Geographically, the company's operations are centered in India, and there is no indication of substantial international exposure in the provided data. This concentration may pose a risk if the domestic market experiences economic downturns or regulatory changes.

    Looking at the growth trajectory, the company's revenue for the latest period is INR 2.52 billion. While the data does not provide a multi-year growth rate, the positive free cash flow and strong ROE suggest a stable and potentially growing business. The company's capital expenditures were negative INR 420.24 million, indicating that it may have been reducing its capital investments or receiving returns from existing investments.

    The risk assessment for Suraksha Diagnostic Ltd indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could affect its ability to meet short-term obligations without additional financing. However, the low dilution risk suggests that the company is not likely to issue a significant number of new shares in the near future, which is favorable for existing shareholders.

    Recent events and filings do not show any significant changes in the company's operations or financial strategy. The company's IR observations indicate that analysts have a neutral stance, with a mean recommendation of 3.00, which is a hold rating. There are no strong buy or buy recommendations, and only one hold recommendation, suggesting that the market is not particularly bullish or bearish on the stock at this time.

    - Suraksha Diagnostic Ltd has a strong return on equity (15.07%) and return on assets (9.54%), indicating effective use of equity and assets to generate profits. - The company's debt-to-equity ratio of 0.42 suggests a conservative capital structure with a relatively low reliance on debt financing. - The company's liquidity position is characterized as medium, with a current ratio of 1.1, indicating it has sufficient short-term assets to cover its short-term liabilities. - The company's revenue is primarily concentrated in its core diagnostic services, with no significant diversification into other segments. - Analysts have a neutral stance on the stock, with a mean recommendation of 3.00, which is a hold rating, and no strong buy or buy recommendations.

    Key takeaways
    • Suraksha Diagnostic Ltd (SURK.NS) is a healthcare services company operating within the Healthcare Facilities & Services industry.
    • The firm generates service revenue through its diagnostic operations, though specific segment or geographic breakdowns are not disclosed.
    • Headquartered in India, the company is primarily listed on the National Stock Exchange of India.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $304,05
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $2.11B
    Net cash
    -$888.9M
    Current ratio
    1.1
    Debt / equity
    0.4
    ROA
    9.5%
    ROE
    15.1%
    Cash conversion
    199.0%
    CapEx / revenue
    -16.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold1
    Sell0
    Strong sell0
    12-month price target$285,00 · Median $285,00
    Low $285,00High $285,00
    Operating income · consensus499,0M INR

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$285,00
    Mean$285,00
    Median$285,00
    High$285,00
    Spot$304,05
    −6.3 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin18,3 %Above P75
    Net Margin12,6 %Above P75
    ROE15,1 %Above P75
    Capex / Rev-16,7 %Bottom quartile
    D/E0,42Above median
    Cash Conv1,99Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Suraksha Diagnostic Ltd Market data — financials · 2026-05-29
    • Suraksha Diagnostic Ltd Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SURK.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage